Business ❯ Finance ❯ Market Analysis ❯ Stock Ratings

Analyst Ratings

CrowdStrike Extends ARR Ambition to $20 Billion by FY36 After Fal.Con Rally

Analysts weigh lofty valuation against an AI-first expansion plan.

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab